Primer: Hangzhou Jiuyuan Genetic Biopharmaceutical (2566 HK) - Aug 2026
Hangzhou Jiuyuan is a domestic leader in select biopharmaceutical segments, particularly orthopedics with its key product Guyoudao (rhBMP-2),...
95 Views
Hong Kong Buybacks Weekly (Feb 6th): Zto Express, Xiaomi, Kingsoft
We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Zto Express (2057...
275 Views
Pre-IPO Shaanxi Micot Pharmaceutical Technology - About the Pipeline and the Concerns Behind
In addition to fierce competition, Micot lacks experience in drug promotion and sales. The core drivers of valuation depend on future clinical data...
659 Views
Pre-IPO Hangzhou Sciwind Biosciences - Thoughts About the Industry and The GLP-1 Pipeline
Due to fierce competition, Sciwind's pipeline face challenges in head-to-head trial/commercialization.Peak sales of XW003/XW004/XW014 estimated at...
518 Views
Pre-IPO Guangzhou Innogen Pharmaceutical Group (PHIP Updates) - Some Points Worth the Attention
Innogen's crazy IPO debut is due to the resonance of retail investors' enthusiasm/institutional arbitrage/bubble in biotech sector.Reasonable...
1.1k Views